[Courtesy of SCM Lifescience]
SEOUL -- PBS Biotech, the American manufacturer of single-use bioreactors, joined hands with SCM Lifescience, the South Korean developer of high-purity allogeneic stem cell therapeutics, to develop and optimize the process of producing up to 80 liters of stem cells by using a three-dimensional incubator.
The two companies signed a deal to develop a mass-production process by the first half of next year. The three-dimensional method is cost-effective as it enables a short incubation time, a high yield of production and the mass production of cells with consistent quality, making it suitable for the commercialization of cell therapies.
SCM Lifesciences suggested that the three-dimensional cultivation would expedite the commercialization of stem cell therapies. Along with the separation and culture of high-purity and highly efficacious stem cells, the company has carried out clinical trials employing stem cell therapeutic agents. The clinical trial of therapeutic agents for multi-dose therapy of atopic dermatitis has been approved in South Korea.
SCM Lifescience is involved in the development of therapeutic agents for acute respiratory distress syndrome (ARDS), COVID 19 and septicemia. The company has expanded its business scope into next-generation immuno-cytological therapeutics, such as dendritic cell-based vaccines against cancers.
reporter
Lim Chang-won
cwlim34@ajunews.com
